🇺🇸 Namuscla in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 1
Most-reported reactions
- Therapeutic Product Effect Increased — 1 report (100%)
Namuscla in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Namuscla approved in United States?
Namuscla does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Namuscla in United States?
Grete Andersen, MD is the originator. The local marketing authorisation holder may differ — check the official source linked above.